Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Trellus Health PLC ( (GB:TRLS) ) has issued an announcement.
Trellus Health has granted options over 807,541 ordinary shares to its chairman, Kevin Murphy, under the company’s existing share option plan at an exercise price of 0.525p, matching the pricing of a recent loan note arrangement with Mount Sinai. The options vest in 12 equal quarterly instalments over approximately 39 months and are subject to standard lock-in and leaver provisions; the independent directors say the award is fair and reasonable and is intended to align the chairman’s incentives closely with those of shareholders, signalling continued emphasis on governance and long-term value creation as the company pursues its chronic-condition management strategy.
The most recent analyst rating on (GB:TRLS) stock is a Sell with a £0.38 price target. To see the full list of analyst forecasts on Trellus Health PLC stock, see the GB:TRLS Stock Forecast page.
Spark’s Take on GB:TRLS Stock
According to Spark, TipRanks’ AI Analyst, GB:TRLS is a Neutral.
The score is primarily weighed down by weak financial performance—large ongoing losses and persistent cash burn—despite the benefit of having no debt. Technical signals also remain clearly bearish (below key moving averages with negative momentum), while valuation provides limited support because the company is unprofitable and has no stated dividend yield.
To see Spark’s full report on GB:TRLS stock, click here.
More about Trellus Health PLC
Trellus Health plc is a UK- and US-based healthcare company listed on AIM that provides value-based digital solutions for managing complex chronic conditions. Its core offering, Trellus Elevate, is a whole-person, technology-enhanced platform that integrates proprietary resilience-based methodology, data analytics, tools, and expert coaching to support self-management and continuous, personalised care. Initially focused on high-cost gastrointestinal diseases such as inflammatory bowel disease, the platform has demonstrated significant reductions in hospitalisations and emergency room visits, and the company also partners with pharmaceutical firms to support clinical trials and commercial patient support programmes.
Average Trading Volume: 532,049
Technical Sentiment Signal: Sell
Current Market Cap: £646K
See more data about TRLS stock on TipRanks’ Stock Analysis page.